Comparative Pharmacology
Head-to-head clinical analysis: SEYSARA versus TERRAMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SEYSARA versus TERRAMYCIN.
SEYSARA vs TERRAMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sarecycline is a tetracycline-class antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain. It also has anti-inflammatory properties through inhibition of neutrophil chemotaxis and reduction of pro-inflammatory cytokines.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
100 mg orally once daily with food.
250-500 mg orally every 6 hours or 1-2 g intravenously every 12 hours. Maximum oral dose: 2 g/day.
None Documented
None Documented
The terminal elimination half-life after oral administration is approximately 12 hours (range 10-14 hours), supporting once-daily dosing.
Terminal elimination half-life: 8-10 hours in normal renal function; prolonged to 20-40 hours in severe renal impairment (creatinine clearance <10 mL/min).
Renal excretion of unchanged drug accounts for approximately 66% of the administered dose; fecal elimination is about 33%.
Renal (primarily glomerular filtration, 20-60% unchanged in urine), biliary/fecal (10-30% via bile into feces).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic